Karen Firestone is Director at Amylyx Pharmaceuticals, Inc. (AMLX). They have made 5 open-market trades across 1 company since 2023, most recently 2026-08-31.
CIK 0001969821
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $351K since 2023, never a sale. Across 5 scored buys the stock is up 32.9% at ninety days, and 27.8 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| AMLX | 116,900 | $3.1M |
Shares reported on the most recent Form 4, priced at the 2026-09-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 80% | 60% |
| Avg Move | -2.6% | +17.1% | +32.9% |
| Alpha | -3.4% | +15.6% | +27.8% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AMLX | BUY | 2026-05-21 | 2026-05-26 | $13.51 | $51K | -5.1% | +24.5% | +172.3% |
| AMLX | BUY | 2025-12-23 | 2025-12-23 | $12.45 | $101K | -9.7% | +28.8% | +7.4% |
| AMLX | BUY | 2024-09-05 | 2024-09-09 | $2.13 | $107K | +12.1% | +31.9% | +89.9% |
| AMLX | BUY | 2023-12-15 | 2023-12-19 | $14.97 | $60K | +4.8% | +4.2% | -80.0% |
| AMLX | BUY | 2023-03-16 | 2023-03-20 | $31.99 | $32K | -15.1% | -3.8% | -25.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.